Article
Pharmacology & Pharmacy
Qiwei Wu, Xiaodong Ma, Wenhui Zhou, Rong Yu, Jessica M. Rosenholm, Weizhong Tian, Lirong Zhang, Dongqing Wang, Hongbo Zhang
Summary: A stable nanoplatform combining chemotherapy with photodynamic therapy has been established for more effective treatment of pancreatic carcinoma. The designed TPG NPs can carry multiple drugs to improve targeting and enhance therapeutic effects against cancer cells.
Article
Cell Biology
Yao Wang, Xiaolong Miao, Yuancong Jiang, Zelai Wu, Xuhang Zhu, Han Liu, Xiaoying Wu, Jinzhen Cai, Xianfeng Ding, Weihua Gong
Summary: In this study, the combination of anti-IL-6 antibody and NVP-BEZ235 showed enhanced antitumor effects in hepatocellular carcinoma (HCC) by synergistically inhibiting the PI3K/AKT/mTOR signaling pathway. These findings provide guidance for the analysis and clinical treatment of HCC.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Manali Patki, Aishwarya Saraswat, Shraddha Bhutkar, Vikas Dukhande, Ketan Patel
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with Gemcitabine (Gem) as the main treatment, but its efficacy is limited by rapid inactivation by cytidine deaminase (CDA) in pancreatic cancer cells. A study found that a CDA inhibitor, Zebularine (Zeb), synergistically increased Gem-induced cytotoxicity in three pancreatic cancer cell lines. This combination treatment showed potential as a future approach for PDAC therapy.
EXPERIMENTAL CELL RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
David J. Wooten, Indu Sinha, Raghu Sinha
Summary: The study aimed to investigate the combination treatment of selenium and Gemcitabine on pancreatic cancer. The results showed that the combination had anti-proliferative and apoptosis-inducing effects on pancreatic cancer cells in vitro, and the combination performed better in both 2D and 3D growth environments.
Article
Chemistry, Multidisciplinary
Seo Yeon Kim, Min Jeong Jo, Moon Sup Yoon, Chae Eun Jin, Yu Been Shin, Jae Min Lee, Hee Ji Shin, Joon Gyo Oh, Jae Min Cho, Hyunjun Kim, Hyunjin Park, Yong-Won Choi, Chun-Woong Park, Jin-Seok Kim, Dae Hwan Shin
Summary: This study developed a drug delivery strategy for pancreatic ductal adenocarcinoma using a thermosensitive gel, which successfully achieved controlled release of drugs based on the researchers' tolerance settings. The gel consisted of gemcitabine (GEM) and the mammalian TOR (mTOR) inhibitor rapamycin (RAPA), demonstrating good cytotoxicity and anti-tumor effects in in vitro and in vivo experiments.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Chemistry, Multidisciplinary
Mubin Tarannum, Md Akram Hossain, Bryce Holmes, Shan Yan, Pinku Mukherjee, Juan L. Vivero-Escoto
Summary: A mesoporous silica nanoparticle (MSN)-based platform is developed for the safe and ratiometric co-delivery of Gem and cisplatin (cisPt) in pancreatic ductal adenocarcinoma (PDAC). The nanoparticles demonstrate synergistic therapeutic outcomes in mouse models and show potential for overcoming resistance to Pt-based drugs. Overall, the platform offers a promising approach for targeted therapy in PDAC.
Article
Oncology
Bessi Qorri, Reza Bayat Mokhtari, William W. Harless, Myron R. Szewczuk
Summary: Drug repurposing in combination with clinical standard chemotherapeutics opens a novel and promising clinical treatment approach for patients with pancreatic cancer. The combination of aspirin and oseltamivir phosphate with chemotherapeutic gemcitabine shows a therapeutic effect on pancreatic cancer cells, modulating cell proliferation, invasion, clonogenicity, and migration.
Article
Pharmacology & Pharmacy
Da Eun Lee, Hyeon Woong Kang, So Yi Kim, Myeong Jin Kim, Jae Woong Jeong, Woosol Chris Hong, Sungsoon Fang, Hyung Sun Kim, Yun Sun Lee, Hyo Jung Kim, Joon Seong Park
Summary: This study demonstrates that the combination of ivermectin and gemcitabine effectively suppresses pancreatic cancer by inhibiting cell proliferation and inducing cell apoptosis through cell cycle arrest and mitochondrial dysfunction. In vivo experiments also support the tumor-inhibiting effect of this combination treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Bihui Li, Xing Zhang, Qianyao Ren, Li Gao, Jing Tian
Summary: Despite promising results in vitro and preclinical studies, the dual PI3K/Akt/mTOR inhibitor NVP-BEZ235 and the ATP-competitive mTOR inhibitor PP242 failed to show inhibitory efficacy against renal cell carcinoma (RCC) in clinical settings. However, they both demonstrated marked effects by targeting TAK1-dependent pathways in RCC cells, especially NVP-BEZ235, suggesting potential application in combination therapy for RCC.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Nanoscience & Nanotechnology
Fu-An Deng, Yi-Bin Liu, Rong-Rong Zheng, Ren-Jiang Kong, Xiang Zhou, Jia-Jia Wang, Hong Cheng, Shi-Ying Li
Summary: In this study, a pure-drug-assembled nanomedicine named CeBez consisting of chlorine e6 (Ce6) and Bez235 (Bez) was designed for chemo-/photodynamic therapy. CeBez showed tumor site targeting and induced cell apoptosis through the generation of singlet oxygen. Moreover, Bez could downregulate mTOR and enhance photodynamic therapy.
ACS APPLIED NANO MATERIALS
(2022)
Article
Cell Biology
Shreya Udawant, Carl Litif, Alma Lopez, Bonnie Gunn, Erin Schuenzel, Megan Keniry
Summary: The study compared the role of the PI3K/AKT/mTOR pathway in GBM tumor metabolism, revealing that PI3K-impacted glycolytic genes are over-expressed and associated with poor prognosis in GBM patients.
Article
Medicine, Research & Experimental
Jun Lu, Xiaowu Jenifer Wu, Amira Hassouna, Kelvin Sheng Wang, Yan Li, Tao Feng, Yu Zhao, Minfeng Jin, Baohong Zhang, Tianlei Ying, Jinyao Li, Lufeng Cheng, Johnson Liu, Yue Huang
Summary: The combination of fucoxanthin, a marine carotenoid, with gemcitabine, a chemotherapeutic agent, enhances the inhibitory effect on pancreatic cancer cells without cytotoxicity to non-cancer cells. This suggests that fucoxanthin has the potential to be used as an adjunct in pancreatic cancer treatment.
BIOMEDICAL REPORTS
(2023)
Article
Multidisciplinary Sciences
Mina Emamzadeh, George Pasparakis
Summary: Pancreatic cancer, a deadly malignancy, is typically treated with gemcitabine but with limited success. This study integrated gemcitabine with gold nanoshells, showing improved therapeutic outcomes after laser irradiation and potential for enhanced anti-tumor effects.
SCIENTIFIC REPORTS
(2021)
Article
Engineering, Biomedical
Gaorui Zhang, Nianlu Li, Yafei Qi, Quanqin Zhao, Jinhua Zhan, Dexin Yu
Summary: This study developed carbonaceous nanoparticles loaded with gemcitabine as nanozymes and theranostic platform for MR-guided ferroptosis-chemo synergetic therapy of pancreatic adenocarcinoma. The nanoparticles effectively promoted ferroptosis therapy and achieved synergetic therapy with gemcitabine. The nanoparticles also had high magnetic susceptibility and were used for simultaneous MRI monitoring of the treatment.
ACTA BIOMATERIALIA
(2022)
Article
Oncology
Fadime Cetin, Sifa Kosba, Huseyin Abdik, Zeynep Busra Bolat
Summary: The combination therapy of NVP-BEZ235 and curcumin has a synergistic effect on neuroblastoma, inhibiting cell growth and inducing apoptosis. These findings suggest that NVP-BEZ235 and curcumin may be promising therapeutic agents for the treatment of neuroblastoma.